U.S. markets closed
  • S&P Futures

    3,758.00
    +1.25 (+0.03%)
     
  • Dow Futures

    30,007.00
    +25.00 (+0.08%)
     
  • Nasdaq Futures

    11,550.00
    +8.25 (+0.07%)
     
  • Russell 2000 Futures

    1,761.40
    +3.30 (+0.19%)
     
  • Crude Oil

    88.45
    0.00 (0.00%)
     
  • Gold

    1,720.20
    -0.60 (-0.03%)
     
  • Silver

    20.76
    +0.10 (+0.51%)
     
  • EUR/USD

    0.9812
    +0.0016 (+0.17%)
     
  • 10-Yr Bond

    3.8260
    +0.0670 (+1.78%)
     
  • Vix

    30.52
    +1.97 (+6.90%)
     
  • GBP/USD

    1.1180
    +0.0011 (+0.10%)
     
  • USD/JPY

    144.9550
    -0.1130 (-0.08%)
     
  • BTC-USD

    20,023.62
    -296.14 (-1.46%)
     
  • CMC Crypto 200

    455.54
    -7.58 (-1.64%)
     
  • FTSE 100

    6,997.27
    -55.35 (-0.78%)
     
  • Nikkei 225

    27,149.76
    -161.54 (-0.59%)
     

Sanofi Lowers Out-Of-Pocket Insulin Cost For Uninsured Patients

·1 min read
  • Sanofi SA (NASDAQ: SNY) said that uninsured diabetes patients in the U.S. will pay no more than $35 for a 30-day supply of insulin, down from $99.

  • Sanofi said the new price would be effective from July 1.

  • The announcement from Sanofi follows House passage (232-193) of the monthly cap in March, with just 12 Republicans voting in favor of the measure.

  • Sanofi, meanwhile, says that all commercially insured people are eligible for its co-pay assistance programs, regardless of income or insurance, “which limits out-of-pocket expenses for a majority of people between $0 and $10.” But the company also confirmed that some diabetics taking Sanofi’s insulins would see savings with the House bill.

  • Reuters said that Sanofi, Eli Lilly And Co (NYSE: LLY), and Novo Nordisk A/S (NYSE: NVO) make up 90% of the U.S. market for insulin. In 2020, Lilly announced a new co-pay scheme that covers most of its insulin products, capping the out-of-pocket cost for insulin to $35 per month.

  • Price Action: SNY shares are up 1.36% at $52.85 during the market session on the last check Wednesday.

  • Photo by Towfiqu Barbhuiya via Unsplash

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.